Chronic viral hepatitis and chronic kidney disease

Postgraduate Medical Journal

Volumn 86, Issue 1018, 2010, Pages 486-492

  Chacko, Elias C ^a   Surrun, Soondal Koomar ^a   Mubarack Sani, T P ^b   Pappachan, Joseph M ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b Pariyaram Medical College   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA; RIBAVIRIN; TENOFOVIR;

CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEMBRANOUS GLOMERULONEPHRITIS; MORBIDITY; MORTALITY; PATHOGENESIS; REVIEW; VIRUS HEPATITIS;

ANTIVIRAL AGENTS; CHRONIC DISEASE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; KIDNEY DISEASES;

EID: 77956045286     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2009.092775     Document Type: Review

References (78)

1. Krane NK, Gaglio P. Viral hepatitis as a cause of renal disease. South Med J 1999;92:354-60. (Pubitemid 29197485)
2. Mackelaite L, Alsauskas ZC, Ranganna K. Renal failure in patients with cirrhosis. Med Clin North Am 2009;93:855-69.
3. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009;49(5 Suppl):S13-21.
4. Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991;324:1457-63.
5. Perico N, Cattaneo D, Bikbov B, et al. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 2009;4:207-20.
6. Galossi A, Guarisco R, Bellis L, et al. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis 2007;16:65-73. (Pubitemid 46548592)
7. Molino C, Fabbian F, Cozzolino M, et al. The management of viral hepatitis in CKD patients: an unresolved problem. Int J Artif Organs 2008;31:683-96.
8. Takekoshi Y, Tanaka M, Shida N, et al. Strong association between membranous nephropathy and hepatitis-B surface antigenaemia in Japanese children. Lancet 1978;2:1065-8. (Pubitemid 9052859)
9. Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol 2004;24:198-211.
10. Bhimma R, Hammond MG, Coovadia HM, et al. HLA class I and II in black children with hepatitis B virus-associated membranous nephropathy. Kidney Int 2002;61:1510-15.
11. Ren J, Wang L, Chen Z, et al. Gene expression profile of transgenic mouse kidney reveals pathogenesis of hepatitis B virus associated nephropathy. J Med Virol 2006;78:551-60.
12. Deng CL, Song XW, Liang HJ, et al. Chronic hepatitis B serum promotes apoptotic damage in human renal tubular cells. World J Gastroenterol 2006;12:1752-6.
13. Nagy J, Bajtai G, Brasch H, et al. The role of hepatitis B surface antigen in the pathogenesis of glomerulopathies. Clin Nephrol 1979;12:109-16. (Pubitemid 10237952)
14. Bhimma R, Coovadia HM, Adhikari M. Hepatitis B virus-associated nephropathy in black South African children. Pediatr Nephrol 1998;12:479-84. (Pubitemid 28396036)
15. Guillevin L, Mahr A, Callard P, et al. French Vasculitis Study Group. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005;84:313-22.
16. Semple D, Keogh J, Forni L, et al. Clinical review: vasculitis on the intensive care unit-part 1: diagnosis. Crit Care 2005;9:92-7.
17. Peña A, Débora MJ, Melgosa M, et al. Membranous nephropathy associated with hepatitis B in Spanish children. Clin Nephrol 2001;55:25-30. (Pubitemid 32041779)
18. Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1995;47:225-30.
19. Bhimma R, Coovadia HM, Kramvis A, et al. Treatment of hepatitis B virus-associated nephropathy in black children. Pediatr Nephrol 2002;17:393-9.
20. Tang S, Lai FM, Lui YH, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005;68:1750-8.
21. Cooke GS, Main J, Thursz MR. Treatment for hepatitis B. BMJ 2010;340:b5429. doi:10.1136/bmj.b5429.
22. Peters MG. Special populations with hepatitis B virus infection. Hepatology 2009;49(5 Suppl):S146-55.
23. Lanini S, Puro V, Lauria FN, et al. Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. BMC Med 2009;7:15.
24. Fabrizi F, Messa P, Martin P. Hepatitis B virus infection and the dialysis patient. Semin Dial 2008;21:440-6.
25. Capeillère-Blandin C, Gausson V, Nguyen AT, et al. Respective role of uraemic toxins and myeloperoxidase in the uraemic state. Nephrol Dial Transplant 2006;21:1555-63. (Pubitemid 43840618)
26. Descamps-Latscha B, Drueke T, Witko-Sarsat V. Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial 2001;14:193-9. (Pubitemid 33720852)
27. Witko-Sarsat V, Rieu P, Descamps-Latscha B, et al. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest 2000;80:617-53.
28. Wong P, Mak S, Wong AK. Management of chronic hepatitis B infection in patients with end-stage renal disease and dialysis. Hep B Annual 2006;3:76-105.
29. London WT, Drew JS, Lustbader ED, et al. Host responses to hepatitis B infection in patients in a chronic hemodialysis unit. Kidney Int 1977;12:51-8.
30. Wong PN, Fung TT, Chan AN, et al. Unusual case of hepatitic cholestasis resembling fibrosing cholestatic hepatitis in a dialysis patient with chronic hepatitis B infection. J Gastroenterol Hepatol 2006;21:1635-7.
31. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49(5 Suppl):S156-65.
32. Lopez-Alcorocho JM, Barril G, Ortiz-Movilla N, et al. Prevalence of hepatitis B, hepatitis C, GB virus C/hepatitis G and TT viruses in predialysis and hemodialysis patients. J Med Virol 2001;63:103-7. (Pubitemid 32146153)
33. Girndt M, Köhler H. Hepatitis B virus infection in hemodialysis patients. Semin Nephrol 2002;22:340-50. (Pubitemid 34790830)
34. Stevens CE, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984;311:496-501.
35. Micozkadioglu H, Zumrutdal A, Torun D, et al. Low dose intradermal vaccination is superior to high dose intramuscular vaccination for hepatitis B in unresponsive hemodialysis patients. Ren Fail 2007;29:285-8. (Pubitemid 46752340)
36. Barraclough KA, Wiggins KJ, Hawley CM, et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis 2009;54:95-103.
37. Radhakrishnan J, Uppot RN, Colvin RB. Case records of the Massachusetts General Hospital. Case 5-2010. A 51-year-old man with HIV infection, proteinuria, and edema. N Engl J Med 2010;362:636-46.
38. Pascual M, Perrin L, Giostra E, et al. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 1990;162:569-70. (Pubitemid 20239986)
39. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-70. (Pubitemid 23056436)
40. Stehman-Breen C, Alpers CE, Couser WG, et al. Hepatitis C virus associated membranous glomerulonephritis. Clin Nephrol 1995;44:141-7.
41. Sabry AA, Sobh MA, Irving WL, et al. A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant 2002;17:239-45.
42. Roccatello D, Fornasieri A, Giachino O, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007;49:69-82. (Pubitemid 44932190)
43. Arase Y, Ikeda K, Murashima N, et al. Glomerulonephritis in autopsy cases with hepatitis C virus infection. Intern Med 1998;37:836-40.
44. Sansonno D, Carbone A, De Re V, et al. Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology (Oxford) 2007;46:572-8. (Pubitemid 46523298)
45. Alpers CE, Kowalewska J. Emerging paradigms in the renal pathology of viral diseases. Clin J Am Soc Nephrol 2007;2(Suppl 1):S6-12.
46. Sansonno D, Gesualdo L, Manno C, et al. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology 1997;25:1237-44. (Pubitemid 27199954)
47. Wong VS, Egner W, Elsey T, et al. Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection. Clin Exp Immunol 1996;104:25-31. (Pubitemid 26103408)
48. Johnson RJ, Willson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int 1994;46:1255-63. (Pubitemid 24330702)
49. Sabharwal S, Delgado-Borrego A, Chung RT. Extrahepatic hepatitis C virus after transplantation: diabetes and renal dysfunction. Liver Transpl 2008; 14(Suppl 2):51-7.
50. Ghany MG, Strader DB, Thomas DL, et al. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
51. Fabrizi F, Lunghi G, Messa P, et al. Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol 2008;21:813-25.
52. Dore MP, Fattovich G, Sepulveda AR, et al. Cryoglobulinemia related to hepatitis C virus infection. Dig Dis Sci 2007;52:897-907. (Pubitemid 46481268)
53. Kamar N, Rostaing L, Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 2006;69:436-9.
54. Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004;65:2335-42.
55. Karkar A. Hepatitis C in dialysis units: the Saudi experience. Hemodial Int 2007;11:354-67. (Pubitemid 46958591)
56. Tsui JI, Vittinghoff E, Shlipak MG, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007;167:1271-6. (Pubitemid 46998498)
57. Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat 2007;14:697-703. (Pubitemid 47414935)
58. Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000;11:1896-902.
59. Contreras AM, Ruiz I, Polanco-Cruz G, et al. End-stage renal disease and hepatitis C infection: comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage. Ann Hepatol 2007;6:48-54. (Pubitemid 46407489)
60. Fabrizi F, Lunghi G, Finazzi S, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 2001;38:1009-15. (Pubitemid 33022178)
61. Rockey D, Caldwell AH, Goodman ZD, et al. AASLD position paper: liver biopsy. Hepatology 2009;49:1017-44.
62. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;34:960-74. (Pubitemid 351451980)
63. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004;78:745-50. (Pubitemid 39244740)
64. Aroldi A, Lampertico P, Montagnino G, et al. Natural history of hepatitis C virus infection in adult renal graft recipients. Transplant Proc 2005;37:940-1.
65. Gentil MA, Pérez-Valdivia MA, Muñoz-Terol JM, et al. Are we still making progress in patient survival after kidney transplantation? Results of a regional registry. Transplant Proc 2009;1:2085-8.
66. Kasprzyk T, Kwiatkowski A, Wszola M, et al. Long-term results of kidney transplantation from HCV-positive donors. Transplant Proc 2007;39:701-3.
67. Lindholm A, Albrechtsen D, Frodin L. Ischemic heart disease: major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995;60:451.
68. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007;18:1584-93.
69. Kidney disease: improving global outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008;109:S1-99.
70. Bruchfeld A, Lindahl K, Stahle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003;18:1573-80. (Pubitemid 36939631)
71. Rendina M, Schena A, Castellaneta NM, et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007;46:768-74. (Pubitemid 46529043)
72. Hosseini Moghaddam SM, Alavian SM, Rahnavardi M. Therapeutic aspects of hepatitis C in hemodialysis patients. Am J Nephrol 2009;29:123-8.
73. Shu KH, Lan JL, Wu MJ, et al. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 2004;77:1894-6.
74. Kamar N, Ribes D, Izopet J, et al. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation 2006;82:853-6. (Pubitemid 44564028)
75. Toth CM, Pascual M, Chung RT, et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 1998;66:1254-8.
76. Centers for Disease Control and Prevention (CDC). Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001;50:1-43.
77. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90. (Pubitemid 28065254)
78. Tsai JF, Jeng JE, Ho MS, et al. Independent and additive effect modification of hepatitis C and B viruses infection on the development of chronic hepatitis. J Hepatol 1996;24:271-6.